Fig. 2

Preclinical Cardiac MRI data. a Anatomy scans: We observed that the LV volume was significantly increased in all experimental groups with the effect being more noticeable in the DOX and DOX/DEX groups compared to the control group at all evaluated time points (blue arrows). Upon analysis, the data also show the ratio of LV mass to volume was decreased in the DOX group compared to the DOX/DEX group, and the LV mass was increased in the control and DOX/DEX groups. Please see Table 1 for quantification; b T2 Measurement to assess edema: We observed that mice exposed to doxorubicin with and without dexrazoxane developed myocardial edema (yellow arrows) compared to the untreated controls group at both 4 and 8 weeks of age. This effect was more noticeable in the DOX group compared to the DOX/DEX group. Please see Table 1 for quantification; c/d). ECV pre T1 (c) and post T1 (d) We observed a distinguishable continuous increase in ECV in the DOX group from 4 to 12 weeks. Although an ECV increase was present as well in the DOX/DEX group, it was not as remarkable as the change observed in the DOX group; e/f Tagged scans -- end systole (e) and end diastole (f). We observed that GLS worsened in the DOX group compared to the other experimental groups as early as 4 weeks. This effect (worsening of GLS) was still observed at 8 weeks in the DOX group, and became evident in the DOX/DEX group. GLS quantification was presented in Fig. 1